Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

News from PTC Therapeutics, Celgene and Heron Therapeutics

March 29, 2018 0

IN THE NEWS PTC THERAPEUTICS PTC Therapeutics (PTCT) stock, which dipped yesterday, probably on news announcing a …

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

March 28, 2018 0

A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares CRISPRs are bacterial immune systems …

Bull or Bear

March 26, 2018 0

The Week in Review #20 THE MARKET - My friend asked: “Are you scared?” “Of what?” …

Exelixis’ and Array’s Enchanting News

March 23, 2018 0

Exelixis: Delightful Overseas Cabozantinib News Ipsen (EPA:IPN) announced that the Committee for Medicinal Products for Human Use …

Regeneron Discovers the Therapeutic Target for Non-Viral Chronic Liver Diseases. Alnylam is Assigned to Discover and Create the Targeted RNAi Therapeutic

March 22, 2018 0

Regeneron (REGN) and Alnylam (ALNY) announced a collaborative agreement aimed at identifying RNAi therapeutics for the chronic liver disease …

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

March 21, 2018 0

In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several …

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

March 20, 2018 0

Arena Pharmaceuticals (ARNA) announced positive Phase 2 results from the OASIS trial for etrasimod in ulcerative colitis (UC). The Drug: Etrasimod is a …

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

March 20, 2018 0

What Do We Make of the Following Good News? HERON THERAPEUTICS Will HTX-011 Help in the …

Exelixis: Further Stretching Its Cabozantinib’s Market

March 16, 2018 0

Exelixis (EXEL) completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabometyx® …

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

March 13, 2018 0

Alnylam (ALNY) announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi …

Highlighting Gene Editing Firms

March 12, 2018 0

The Week in Review #19 Targeting the Root-Cause of Diseases - Investing in the Future is …

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

March 8, 2018 0

Extremely important news has come from Montreal, Canada carrying the announcement by Theratechnologies (TSX:TH) and its partner TaiMed …

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

March 6, 2018 0

Regeneron’s (REGN) pipeline products have still a lot of good news to announce. The latest is about …

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

March 5, 2018 0

On March 4, 2018, Aimmune Therapeutics (AIMT) – a biopharmaceutical company developing treatments for potentially life-threatening food allergies …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

February 27, 2018 0

FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system …

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

February 22, 2018 0

The Food and Drug Administration (FDA) approved AstraZeneca (AZN) Checkpoint inhibitor drug Imfinzi® (durvalumab) for patients with unresectable Stage III non-small …

Gilead Collaboration with Sangamo

February 22, 2018 0

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for …

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

February 21, 2018 0

Portola Pharmaceuticals and the CHMP’s Oral Explanations for Andexanet Alfa and Betrixaban Portola (PTLA) announced that the Committee for …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

News from PTC Therapeutics, Celgene and Heron Therapeutics

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

Bull or Bear

Exelixis’ and Array’s Enchanting News

Regeneron Discovers the Therapeutic Target for Non-Viral Chronic Liver Diseases. Alnylam is Assigned to Discover and Create the Targeted RNAi Therapeutic

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

Exelixis: Further Stretching Its Cabozantinib’s Market

The Prohost Portfolio: Updating the Stock Targets

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

Highlighting Gene Editing Firms

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

Observing Queer Stories

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

Gilead Collaboration with Sangamo

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint